Editorial team · Editor-in-Chief · Last reviewed 2026-05-27

Terra Walman, M.D.
Editor-in-Chief

Terra Walman, M.D. is Editor-in-Chief of SemaglutideGLPOne.com. She oversees the editorial framework, methodology, and original-research output covering compounded semaglutide telehealth, FDA enforcement, and provider transparency. All commercial editorial decisions, ranking applications, and methodology versioning are her responsibility.

Professional credentials & licensure (E-E-A-T)

Medical degree & licensure

  • M.D. — Doctor of Medicine
  • Active U.S. state medical board licensure (verifiable via FSMB DocInfo)
  • Continuing medical education compliance maintained per state licensure requirements
  • Specialty focus: GLP-1 receptor agonist therapy, obesity medicine, clinical pharmacology, telehealth-delivered chronic care

State medical board licensure verification

Public verification of any U.S. physician's status is available through the Federation of State Medical Boards (FSMB) DocInfo lookup:

→ fsmb.org/spex/ — DocInfo physician lookup

Patients and journalists can use the FSMB lookup to verify license status, disciplinary history, and specialty board certifications for any licensed U.S. physician.

Areas of clinical expertise

  • GLP-1 receptor agonist therapy (semaglutide, tirzepatide, orforglipron, dual agonists)
  • Obesity medicine and pharmacotherapy
  • Compounded medication clinical evaluation (503A and 503B frameworks)
  • Telehealth-delivered chronic care protocols
  • Cardiovascular risk reduction (SELECT trial framework)
  • Type 2 diabetes management in the context of GLP-1 therapy
  • FDA compounding regulation and enforcement frameworks
  • Evidence-based provider-quality scoring methodology

Role & responsibilities at SemaglutideGLPOne.com

  • Editor-in-Chief — Oversees all commercial editorial content, provider scoring application, and ranking decisions
  • Methodology owner — Maintains and versions the six-pillar transparency rubric (currently v3.0)
  • Investigations lead — Conducts deep-dive provider reviews, FDA enforcement reporting, pricing-index verification
  • Corrections oversight — Reviews and approves reader-submitted corrections at /corrections.html
  • External liaison — Responsible for relationships with regulatory observers, pharmacy boards, and clinical-trial registries

Conflicts of interest (full transparency)

  • Compensation: Employed by Publisher Partners LLC (the publisher). Salaried — not commission-based on affiliate referral volume.
  • Direct financial relationships with reviewed providers: None.
  • Equity in reviewed providers: None.
  • Pharmaceutical companies: No relationships with Novo Nordisk, Eli Lilly, or any GLP-1 manufacturer.
  • Compounding pharmacies: No relationships with Empower, Strive, Hallandale, Medivera, Absolute, RedRock, or any other compounding pharmacy.

Articles & reviews by this clinician

Editorial standards practiced
  • Every commercial claim is paired with evidence at /evidence.html
  • Every medical claim is reviewed for clinical accuracy by a board-certified M.D.
  • Every correction is logged publicly at /corrections.html
  • Every ranking-change is documented in the monthly change log
  • No provider can pay to rank higher — see /how-we-make-money.html